Crossject SA
PAR:ALCJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mask Investments Ltd
NSE:MASKINVEST
|
IN |
Crossject SA
Operating Income
Crossject SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Crossject SA
PAR:ALCJ
|
Operating Income
-€11.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
|
Guerbet SA
PAR:GBT
|
Operating Income
€8.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-18%
|
|
|
Affluent Medical SAS
PAR:AFME
|
Operating Income
-€7.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Crossject SA
Glance View
Crossject SA manufactures and markets needle-free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The firm has industrial partnerships with Hirtenberger and Recipharm.
See Also
What is Crossject SA's Operating Income?
Operating Income
-11.4m
EUR
Based on the financial report for Jun 30, 2025, Crossject SA's Operating Income amounts to -11.4m EUR.
What is Crossject SA's Operating Income growth rate?
Operating Income CAGR 10Y
-6%
Over the last year, the Operating Income growth was 5%. The average annual Operating Income growth rates for Crossject SA have been 3% over the past three years , -6% over the past five years , and -6% over the past ten years .
